Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis

Mi Ni Lee, Shi Nai Lee, Se Hee Kim, Bora Kim, Bo Kyung Jung, Ji Hae Seo, Ji Hyeon Park, Jae Hoon Choi, Sun Hee Yim, Mi Ran Lee, Jong Gil Park, Ji Young Yoo, Jeong Hun Kim, Seung Taek Lee, Hwan Mook Kim, Sandra Ryeom, Kyu Won Kim, Goo Taeg Oh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1α, triggering its degradation, and thus may play a role in decreased expression of VEGFA.Methods We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A 225 acetylation of Lys532 in HIF-1α, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1α/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than. 05 were considered statistically significant.Results ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than Apc Min/+ mice (n = 21) (number of intestinal polyps per mouse: Apc Min/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P <. 001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P <. 01). Moreover, overexpression of mARD1A 225 decreased VEGFA expression and microvessel density in tumor xenografts (P <. 04) and ApcMin/+ intestinal polyps (P =. 001). Mutation of lysine 532 of HIF-1α in B16F10-mARD1A225 cells prevented HIF-1α degradation and inhibited the antimetastatic effect of mARD1A225 (P <. 001).Conclusion mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.

Original languageEnglish
Pages (from-to)426-442
Number of pages17
JournalJournal of the National Cancer Institute
Volume102
Issue number6
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

Hypoxia-Inducible Factor 1
Intestinal Polyps
Neoplasm Metastasis
Vascular Endothelial Growth Factor A
Growth
Neoplasms
Proteins
Transgenic Mice
Polyps
Microvessels
Cell Hypoxia
Acetylation
Heterografts
Lysine
Melanoma
Stomach
Immunohistochemistry
Confidence Intervals
Cell Line
Mutation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Mi Ni ; Lee, Shi Nai ; Kim, Se Hee ; Kim, Bora ; Jung, Bo Kyung ; Seo, Ji Hae ; Park, Ji Hyeon ; Choi, Jae Hoon ; Yim, Sun Hee ; Lee, Mi Ran ; Park, Jong Gil ; Yoo, Ji Young ; Kim, Jeong Hun ; Lee, Seung Taek ; Kim, Hwan Mook ; Ryeom, Sandra ; Kim, Kyu Won ; Oh, Goo Taeg. / Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis. In: Journal of the National Cancer Institute. 2010 ; Vol. 102, No. 6. pp. 426-442.
@article{c926a1e145974fc89dc832920d404edd,
title = "Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis",
abstract = "Background Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1α, triggering its degradation, and thus may play a role in decreased expression of VEGFA.Methods We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A 225 acetylation of Lys532 in HIF-1α, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1α/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than. 05 were considered statistically significant.Results ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than Apc Min/+ mice (n = 21) (number of intestinal polyps per mouse: Apc Min/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95{\%} confidence interval [CI] = 41.8 to 48.6; P <. 001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P <. 01). Moreover, overexpression of mARD1A 225 decreased VEGFA expression and microvessel density in tumor xenografts (P <. 04) and ApcMin/+ intestinal polyps (P =. 001). Mutation of lysine 532 of HIF-1α in B16F10-mARD1A225 cells prevented HIF-1α degradation and inhibited the antimetastatic effect of mARD1A225 (P <. 001).Conclusion mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.",
author = "Lee, {Mi Ni} and Lee, {Shi Nai} and Kim, {Se Hee} and Bora Kim and Jung, {Bo Kyung} and Seo, {Ji Hae} and Park, {Ji Hyeon} and Choi, {Jae Hoon} and Yim, {Sun Hee} and Lee, {Mi Ran} and Park, {Jong Gil} and Yoo, {Ji Young} and Kim, {Jeong Hun} and Lee, {Seung Taek} and Kim, {Hwan Mook} and Sandra Ryeom and Kim, {Kyu Won} and Oh, {Goo Taeg}",
year = "2010",
month = "3",
day = "1",
doi = "10.1093/jnci/djq026",
language = "English",
volume = "102",
pages = "426--442",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

Lee, MN, Lee, SN, Kim, SH, Kim, B, Jung, BK, Seo, JH, Park, JH, Choi, JH, Yim, SH, Lee, MR, Park, JG, Yoo, JY, Kim, JH, Lee, ST, Kim, HM, Ryeom, S, Kim, KW & Oh, GT 2010, 'Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis', Journal of the National Cancer Institute, vol. 102, no. 6, pp. 426-442. https://doi.org/10.1093/jnci/djq026

Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis. / Lee, Mi Ni; Lee, Shi Nai; Kim, Se Hee; Kim, Bora; Jung, Bo Kyung; Seo, Ji Hae; Park, Ji Hyeon; Choi, Jae Hoon; Yim, Sun Hee; Lee, Mi Ran; Park, Jong Gil; Yoo, Ji Young; Kim, Jeong Hun; Lee, Seung Taek; Kim, Hwan Mook; Ryeom, Sandra; Kim, Kyu Won; Oh, Goo Taeg.

In: Journal of the National Cancer Institute, Vol. 102, No. 6, 01.03.2010, p. 426-442.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis

AU - Lee, Mi Ni

AU - Lee, Shi Nai

AU - Kim, Se Hee

AU - Kim, Bora

AU - Jung, Bo Kyung

AU - Seo, Ji Hae

AU - Park, Ji Hyeon

AU - Choi, Jae Hoon

AU - Yim, Sun Hee

AU - Lee, Mi Ran

AU - Park, Jong Gil

AU - Yoo, Ji Young

AU - Kim, Jeong Hun

AU - Lee, Seung Taek

AU - Kim, Hwan Mook

AU - Ryeom, Sandra

AU - Kim, Kyu Won

AU - Oh, Goo Taeg

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Background Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1α, triggering its degradation, and thus may play a role in decreased expression of VEGFA.Methods We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A 225 acetylation of Lys532 in HIF-1α, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1α/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than. 05 were considered statistically significant.Results ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than Apc Min/+ mice (n = 21) (number of intestinal polyps per mouse: Apc Min/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P <. 001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P <. 01). Moreover, overexpression of mARD1A 225 decreased VEGFA expression and microvessel density in tumor xenografts (P <. 04) and ApcMin/+ intestinal polyps (P =. 001). Mutation of lysine 532 of HIF-1α in B16F10-mARD1A225 cells prevented HIF-1α degradation and inhibited the antimetastatic effect of mARD1A225 (P <. 001).Conclusion mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.

AB - Background Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1α, triggering its degradation, and thus may play a role in decreased expression of VEGFA.Methods We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A 225 acetylation of Lys532 in HIF-1α, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1α/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than. 05 were considered statistically significant.Results ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than Apc Min/+ mice (n = 21) (number of intestinal polyps per mouse: Apc Min/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P <. 001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P <. 01). Moreover, overexpression of mARD1A 225 decreased VEGFA expression and microvessel density in tumor xenografts (P <. 04) and ApcMin/+ intestinal polyps (P =. 001). Mutation of lysine 532 of HIF-1α in B16F10-mARD1A225 cells prevented HIF-1α degradation and inhibited the antimetastatic effect of mARD1A225 (P <. 001).Conclusion mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=77949943221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949943221&partnerID=8YFLogxK

U2 - 10.1093/jnci/djq026

DO - 10.1093/jnci/djq026

M3 - Article

C2 - 20194889

AN - SCOPUS:77949943221

VL - 102

SP - 426

EP - 442

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -